Close

Have A Question?


Connect with Camargo today.

Contact Us
Blog & Resources Camargo Blog Clinical

The Camargo Blog

Get insight and information from our team of experts to improve your pharmaceutical development and commercialization strategy.


September 14th, 2009

A Treatment IND is NOT the Same as an IND

May 29th, 2009

MAP Pharmaceutials 505(b)(2) Dihydroergotamine Orally Inhaled Product Meets Phase 3 Goals

May 15th, 2009

505(b)(2) IV Acetaminophen

May 15th, 2009

Quick-release Bromocriptine Mesylate Approved

April 17th, 2009

505(b)(2) Program: BTG’s Paxclitaxel Gel for Oesophageal Cancer

March 19th, 2009

One vs. Two Batches for Single-Dose and Multiple-Dose Studies

February 2nd, 2009

Dexlansoprazole Approved for the Treatment of GERD

January 29th, 2009

Watson’s 505(b)(2) Overactive Bladder Gel Approved by FDA

December 3rd, 2008

505(b)(2) Combination Meets Phase 3 Goals

August 22nd, 2008

Modeling Using Dissolution Data

June 7th, 2008

Indevus’ Stock Drops 70% on FDA’s Request for More Safety Data

April 23rd, 2008

505(b)(2) Patent & Marketing Exclusivity

February 7th, 2008

A Single Phase 3 Trial Needed for 505(b)(2) Approval of a Combination Drug

January 17th, 2008

505(b)(2) with Only Phase 1 Study

January 16th, 2008

505(b)(2)—Part 2: The Assessment: Timeline, Cash Flows

December 12th, 2007

505(b)(2)—Part 2: The Assessment: Clinical Marketing Assessment

December 10th, 2007

505(b)(2)—Part 2: The Assessment: Clinical Development Plan

December 10th, 2007

505(b)(2)—Part 2: The Assessment: Regulatory Strategy

December 7th, 2007

505(b)(2)—Part 2: The Assessment: Clinical Pharmacology

December 1st, 2007

505(b)(2)—Part 2: The Assessment: Pharmacokinetic Review

November 16th, 2007

505(b)(2) Combo Plavix/Prilosec

November 8th, 2007

505(b)(2)—Part 2: The Assessment: Safety Review

November 6th, 2007

505(b)(2)—Part 2: The Assessment: Efficacy Review

October 28th, 2007

505(b)(2)—Freedom from Generic Competition—Exclusivity Issues

Page 2 of 2


Camargo Pharmaceutical Services provides comprehensive drug development solutions, specializing in customized programs including the 505(b)(2) pathway.


Contact
Headquarters
9825 Kenwood Road
Suite 203
Cincinnati OH, 45242
Durham Office
2505 Meridian Parkway
Suite 150
Durham NC, 27713
Phone 513.561.3329
Toll Free 888.451.5708
Subscribe for our Latest Insights